EGFR

November 21, 2023

VUMC scientists discover key step to kidney fibrosis

Researchers at Vanderbilt University Medical Center for the first time have shown that activation of the epidermal growth factor receptor (EGFR) is essential for the development of kidney fibrosis, tissue scarring following injury that can lead to kidney failure.

By Bill Snyder
August 25, 2022

Inflammatory driver of obesity

Blocking the EGF receptor signaling pathway in immune system macrophages represents a new target for improving insulin resistance in people with obesity.

By Sarah E. Glass
July 28, 2022

Study reveals need for matching targeted therapies with EGFR subtypes

A Vanderbilt study suggests that clinicians should take a deeper dive into distinguishing EGFR mutations when prescribing targeted therapies for non-small-cell lung cancers.

By Tom Wilemon
x-ray of stomach
April 7, 2022

New prognosis predictor and target for gastric cancer

The protein CGA — a subunit of glycoprotein hormones — is a biomarker that predicts chemoresistance in gastric cancer and could be targeted along with EGFR to restore chemosensitivity.

By Sarah E. Glass
September 21, 2021

The role of polarity in early cancer

Mutations in the protein epiregulin, an EGF receptor ligand, affect larger epithelial cell reorganization and may contribute to early cancer development, Vanderbilt researchers discovered.

By VUMC News and Communications
August 25, 2020

Blocking tumor ‘signals’ and ‘fuel’

Combining two drugs reduced colorectal cancer cell growth in vitro and in an animal model, suggesting the combination may be a promising treatment for patients.

By Leigh MacMillan
July 30, 2020

Protein study may be key to treating fibrotic diseases

A protein linked to amyotrophic lateral sclerosis (ALS), a progressive neurological disease that causes muscle weakness, may be a key to treating fibrotic disease of the kidneys and other organs, researchers at Vanderbilt University Medical Center reported recently.
By Bill Snyder
July 25, 2019

Sex differences in kidney injury

Men are more susceptible to progressive kidney disease than women; new VUMC studies point to differences in the expression and activation of the EGF receptor.
By Kelsey Herbers
October 12, 2018

Targeting diabetic kidney disease

Pathways activated by the epidermal growth factor receptor may be attractive targets to treat diabetic kidney disease, according to new findings from Vanderbilt investigators.
By Sanjay Mishra
August 16, 2018

YAP after acute kidney injury

Activation of the signaling protein YAP may be a target for treating acute kidney injury, which affects up to 20 percent of hospitalized patients.
By Sanjay Mishra
October 17, 2017

Researchers find novel mechanism of resistance to anti-cancer drugs

Vanderbilt investigators have discovered a novel non-genetic cause of resistance to the targeted anti-cancer therapy cetuximab. Their findings, reported this week in Nature Medicine, suggest a strategy for overcoming this resistance.
By Leigh MacMillan
October 13, 2017

New tools to combat kidney fibrosis

Vanderbilt investigators have developed a new mouse model of kidney fibrosis, which provides a platform for identifying new targets and treatment strategies.
By Leigh MacMillan
May 18, 2017

Glowing receptors help find and track cancerous growth

Under the microscope, they sparkle like emeralds, these molecules that may hold a key to understanding — and stopping — cancerous growth.
By Bill Snyder
1 2